**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-105. (Cancelled)

Claim 106. (Currently Amended): An isolated, non-tumorigenic~~, regional-identity unrestricted, pluripotent~~ cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal ~~or glial~~ cells derived from the embryonic stem cell-derived neural precursor cells,

the composition being obtainable by:

(a) culturing murine or human embryonic stem cells that are not human genetically modified embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium, the first medium comprising bFGF;

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium, the second medium comprising bFGF and EGF; and

(d) culturing the cells from (c) in a third growth factor-containing serum-free medium, the third medium comprising bFGF and PDGF, to obtain the cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal ~~or glial~~ cells derived from the embryonic stem cell-derived neural precursor cells~~,~~

~~thereby producing the isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells~~.

Claim 107. (Previously Presented): The cell composition according to claim 106, wherein the embryonic stem cells in step (a) are in the form of cell aggregates.

Claim 108. (Previously Presented): The cell composition according to claim 106, wherein the cells of steps (c) and (d) grow as a monolayer.

Claim 109. (Previously Presented): The cell composition according to claim 106, comprising cells with neuronal, astroglial or oligodendroglial properties.

Claim 110. (Previously Presented): The cell composition according to claim 106, wherein the embryonic stem cells are obtained after nuclear transfer into oocytes.

Claim 111. (Previously Presented): The cell composition according to claim 106, wherein the embryonic stem cells are obtained from embryonic germ cells.

Claim 112. (Previously Presented): The cell composition of claim 106, wherein the embryonic stem cells in (a) are cultured in serum-free medium.

Claim 113. (Previously Presented): The cell composition of claim 106, wherein the cell aggregates are embryoid bodies.

Claim 114. (Previously Presented): A cell library comprising cells according to claim 106, which are autologous and nonautologous cells.

Claims 115-117. (Cancelled)

Claim 118. (Currently Amended): An isolated, non-tumorigenic~~, regional identity unrestricted, pluripotent~~ cell composition comprising neural spheres, wherein the neural spheres consist essentially of embryonic stem cell-derived neural precursor cells, and neuronal ~~or glial~~ cells derived from the embryonic stem cell-derived neural precursor cells,

the composition being obtainable by:

(a) culturing murine or human embryonic stem cells that are not human genetically modified embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium, the first medium comprising bFGF; and

(c) culturing the cells from (b) in a second growth factor-containing, serum-free medium, the second medium comprising bFGF and EGF, to produce neural spheres consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal ~~or glial~~ cells derived from the embryonic stem cell-derived neural precursor cells,

thereby producing the isolated, non-tumorigenic~~, regional identity unrestricted, pluripotent~~ cell composition comprising neural spheres~~, wherein the neural spheres consist essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells~~.

Claim 119. (Previously Presented): The cell composition according to claim 118, wherein the embryonic stem cells in (a) are in the form of cell aggregates.

Claim 120. (Previously Presented): The cell composition of claim 118, wherein the cell aggregates are embryoid bodies.

Claim 121. (Previously Presented): The cell composition of claim 118, wherein the embryonic stem cells in (a) are cultured in serum-free medium.

Claim 122. (Previously Presented): The cell composition according to claim 118, wherein the embryonic stem cells are obtained after nuclear transfer into oocytes.

Claim 123. (Previously Presented): The cell composition according to claim 118, wherein the embryonic stem cells are obtained from embryonic germ cells.

Claim 124. (Previously Presented): A cell library comprising cells according to claim 118, which are autologous and nonautologous cells.

Claims 125-136. (Cancelled)

Claim 137. (Currently Amended): A pharmaceutical composition comprising the an isolated, non-tumorigenic ~~regional-identity unrestricted, pluripotent~~ cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal ~~or glial~~ cells derived from the embryonic stem cell-derived neural precursor cells,

the composition being obtainable by:

(a) culturing murine or human embryonic stem cells that are not human genetically modified embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium, the first medium comprising bFGF;

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium, the second medium comprising bFGF and EGF; and

(d) culturing the cells from (c) in a third growth factor-containing serum-free medium, the third medium comprising bFGF and PDGF, to obtain the cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal ~~or glial~~ cells derived from the embryonic stem cell-derived neural precursor cells~~,~~

~~thereby producing the isolated, non-tumorigenic, regional-identity unrestricted, pluripotent cell composition consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells~~.

Claim 138. (Currently Amended): A pharmaceutical composition comprising an isolated, non-tumorigenic~~, regional-identity unrestricted, pluripotent~~ cell composition comprising neural spheres, wherein the neural spheres consist essentially of embryonic stem cell-derived neural precursor cells, and neuronal ~~or glial~~ cells derived from the embryonic stem cell-derived neural precursor cells,

the composition being obtainable by:

(a) culturing murine or human embryonic stem cells that are not human genetically modified embryonic stem cells to produce neural precursor cells;

(b) culturing the neural precursor cells from (a) in a first growth factor-containing serum-free medium, the first medium comprising bFGF; and

(c) culturing the cells from (b) in a second growth factor-containing serum-free medium, the second medium comprising bFGF and EGF, to produce neural spheres consisting essentially of embryonic stem cell-derived neural precursor cells, and neuronal ~~or glial~~ cells derived from the embryonic stem cell-derived neural precursor cells,

thereby producing the isolated, non-tumorigenic~~, regional identity unrestricted, pluripotent~~ cell composition comprising neural spheres~~, wherein the neural spheres consist essentially of embryonic stem cell-derived neural precursor cells, and neuronal or glial cells derived from the embryonic stem cell-derived neural precursor cells~~.

Claim 139. (Canceled)